Reltecimod (TFA)

• Description:

  Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs) [1].

• Product Name Alternative:

  AB-103 (TFA)

• UNSPSC:

  12352209

• Target:

  Bacterial; CD28

• Type:

  Peptides

• Related Pathways:

  Anti-infection; Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection; Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/reltecimod-tfa.html

• Purity:

  99.78

• Solubility:

  DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; adjust pH to 3 with HCl)

• Smiles:

  OC (C=C1) =CC=C1C[C@@H] (C (N[C@@H] (CC (O) =O) C (N[C@H] (C) C (O) =O) =O) =O) NC ([C@H] (C) NC ([C@H] (C (C) C) NC ([C@H] (CC (C) C) NC ([C@H] (CCSC) NC ([C@H]2N (CCC2) C ([C@H] (CO) NC ([C@H] (N) C) =O) =O) =O) =O) =O) =O) =O.OC (C (F) (F) F) =O.[x]

• Molecular Formula:

  C46H72N10O15S.xC2HF3O2

• Molecular Weight:

  1037.19 (free base)

• References & Citations:

  [1]Edgar, R., Tarrio, M.L., Maislin, G. et al. Treatment with One Dose of Reltecimod is Superior to Two Doses in Mouse Models of Lethal Infection. Int J Pept Res Ther 26, 1669–1683 (2020) .

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Peptides

• Clinical Information:

  Phase 3